Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib.

BMC medical genomics - 23 Jun 2022

Chen Yan, Jiang Bo, He Yuange, Zhang Chu, Zhou Wenjie, Fang Cheng, Gu Dejian, Zhang Minxia, Ji Mei, Shi Juntao, Yang Xin

Abstract excerpt

BACKGROUND: Targeted therapy has revolutionized the treatment of patients with malignancies harboring mutations in driver genes and has brought a favorable survival benefit to the population with actionable oncogenic mutations. In recent years, the MET exon14 skipping mutation has been recognized as a potentially promising therapeutic target in non-small cell lung cancer (NSCLC). These changes are mutually...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Anaplastic Lymphoma Kinase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to B7-H1 Antigen

Share to Carcinoma, Non-Small-Cell Lung

Share to Crizotinib

Share to Protein Kinase Inhibitors

Share to Protein-Tyrosine Kinases

Share to Proto-Oncogene Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 35739536
DOI: 10.1186/s12920-022-01291-z
PMCID: PMC9229853

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib.PMID 35739536Read ↗

Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 SkippingSemantic proximity Read ↗

Crizotinib in MET Exon 14-Mutated or MET-Amplified in Advanced Disease Non-Small Cell Lung Cancer: A Retrospective, Single Institution Experience.Semantic proximity Read ↗

Phase 2 trial of crizotinib in Japanese patients with advanced NSCLC harboring a MET gene alteration: a Co-MET study.Semantic proximity Read ↗

Responses to crizotinib and cabozantinib in patient with lung adenocarcinoma harboring mesenchymal-epithelial transition factor exon 14 skipping mutation: A case report.Semantic proximity Read ↗

Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options.Semantic proximity Read ↗

Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study.Semantic proximity Read ↗

Aumolertinib-based comprehensive treatment for an uncommon site of EGFR exon 20 insertion mutations with multiple metastases non-small cell lung cancer: a case report.Semantic proximity Read ↗

Advances in the management of non-small-cell lung cancer harbouring EGFR exon 20 insertion mutationsSemantic proximity Read ↗

The Clinical Pathological Spectrum and Prognosis of NSCLC with EGFR Exon20 InsertionsSemantic proximity Read ↗

Durable Response to Immunotherapy Plus Chemotherapy in a Patient With Untreated, Brain-metastatic, EGFR Exon 20 Insertion Mutation Lung AdenocarcinomaSemantic proximity Read ↗

Management of Non-small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations.Semantic proximity Read ↗

EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectivesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.